NCT02012296View on ClinicalTrials.gov

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 13, 2013

Primary Completion Date

June 10, 2019

Study Completion Date

August 1, 2020

Conditions
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

enzalutamide

Given PO

DRUG

mifepristone

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (4)

48201

Wayne State University Karmanos Cancer Institute, Detroit

60201

NorthShore University Health System, Evanston

62526

Cancer Care Specialists of Central Illinois (Decatur) /Decatur Memorial Hospital, Decatur

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT02012296 - Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter